Concurrent capecitabine radiosensitization (825 mg/m² PO BID on RT days only) — paired with conventionally fractionated GI chemoradiation
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
Contenu clinique provisoire : il ne s'agit pas d'une ordonnance. Un oncologue doit vérifier les sources originales, l'applicabilité et le statut de révision.
| Composantes | DRUG-CAPECITABINE |
|---|
| ID | REG-CAPECITABINE-CRT-CONCURRENT |
|---|---|
| Type | Protocole thérapeutique |
| État | reviewed 2026-05-08 | pending_clinical_signoff | actionability review required |
| Maladies | Aucune déclaration |
| Sources | SRC-ESMO-CRC-2024 SRC-NCCN-COLON-2025 SRC-NCCN-PANCREATIC-2025 SRC-PRODIGE-23-CONROY-2021 |
Notes
Concurrent radiosensitizing capecitabine paired with a conventionally fractionated GI RadiationCourse — distinct from the cyclic palliative capecitabine pattern (REG-CAPECITABINE-PALLIATIVE: 1000 mg/m² BID days 1-14 / 21d for ECOG 3-4 mCRC). The 825 mg/m² PO BID "on RT days only" schedule has no fixed cycle structure: capecitabine is taken Monday through Friday during each week of RT delivery (with the daily dose split BID, typically ~12 hours apart, ideally bracketing the RT fraction), held on weekends and any RT-off days, and stopped with the final RT fraction. Total exposure ~5.5 weeks for the canonical 50.4 Gy / 28 fx pairing. Authored to back-fill the `concurrent_chemo_regimen` FK on two §17 RadiationCourse entities that previously had to leave the field explicitly null with audit-trail comments because no matching regimen existed: - RC-LCCRT-504-28-RECTAL — long-course preoperative chemoradiation for locally advanced rectal cancer (PRODIGE-23 TNT CRT phase / standard arm; SRC-PRODIGE-23-CONROY-2021, SRC-NCCN-COLON-2025, SRC-ESMO-CRC-2024). Conroy 2021, Lancet Oncology n=461; 3-yr DFS 75.7% (TNT) vs 68.5% (standard); pCR 27.8% vs 12.1%. - RC-LAPC-CHEMORADIATION-PDAC — definit...
Utilisé par
Indication
IND-PDAC-LAPC-CHEMORADIATION- IND-PDAC-LAPC-CHEMORADIATIONIND-RECTAL-TNT-LONG-COURSE-PRODIGE23- IND-RECTAL-TNT-LONG-COURSE-PRODIGE23
Cours de radiologie
RC-LAPC-CHEMORADIATION-PDAC- Chimioradiation de consolidation définitive pour l'adénocarcinome pancréatique localement avancé et non réssecable (50,4 Gy / 28 fx)RC-LCCRT-504-28-RECTAL- Chimioradiation préopératoire de longue durée pour le cancer du recte (50.4 Gy / 28 fx + concurrent capecitabine)